Our mission
We strive to revolutionize respiratory infection management by enabling early prediction and optimal treatment of severe conditions.
At SeveriDx, we aim to transform the future of respiratory infection management. Our innovative in-vitro diagnostic kit utilizes a universal prognostic biomarker to predict the severity of respiratory infections early.
This enables clinicians to identify high-risk patients promptly, optimize treatment pathways, and monitor the effectiveness of therapies. By providing timely predictions, SeveriDx helps reduce hospitalizations, prevent severe health outcomes, and decrease healthcare costs.
Our user-friendly, non-invasive test integrates seamlessly into clinical and diagnostic labs, ensuring that healthcare providers can make informed decisions quickly has IP protection till 2041.
We are committed to improving patient care and saving lives through our cutting-edge diagnostic solutions.
Our story
SeveriDx stands out due to its unique technology, strong intellectual property portfolio, and strategic partnerships with leading academic and hospital institutions, clinical study providers, and industry.
Recognizing a pressing need in respiratory infection management, SeveriDx’s journey began in late 2020 with GeneSpector and Charles University’s discovery of a unique biomarker. This finding motivated us on a mission to transform how to approach risk assessment and treatment in respiratory healthcare. By 2021, our idea was validated through a large-scale academic clinical study conducted at Thomayer Faculty Hospital involving almost 1,000 patients. The following year, we applied for a Czech patent that was granted. We later extended by national patent applications submitted in the USA, Europe, Canada, Australia, Japan, China, and Singapore at the beginning of 2024.
In 2024, SeveriDx was officially founded as a spin-off from GeneSpector, assembling a dedicated team and advisory board to drive the mission forward.
SeveriDx offers an advanced diagnostic test with a comprehensive solution that covers everything from sample collection to result analysis for healthcare professionals. To make our product attractive to the biotech, pharma, and healthcare industries, SeveriDx aims to perform all required clinical studies to ensure European regulatory standards for in-vitro diagnostic devices. The company will reach the market via acquisition with a global industry partner/player.
SeveriDx timeline
2024 Q3
SeveriDx foundation
a spin-off of GeneSpector
2024 H2
Setup team and advisory board
partnering (CRO, IVDR certification partner, legal manufacture, marketing, etc.)
2024 H2
Clinical trial preparation for CE IVDR and FDA
2024 Q4
Investment round
2025 – 2026
Clinical studies and certification process
2027 – 2028
Exit
